MoonLake Immunotherapeutics (MLTX)
45.56
-1.20
(-2.57%)
USD |
NASDAQ |
Nov 04, 13:22
MoonLake Immunotherapeutics Shareholders Equity (Quarterly): 520.66M for June 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 520.66M |
| March 31, 2024 | 542.55M |
| December 31, 2023 | 495.68M |
| September 30, 2023 | 424.93M |
| June 30, 2023 | 489.80M |
| Date | Value |
|---|---|
| March 31, 2023 | 42.00M |
| December 31, 2022 | 48.90M |
| September 30, 2022 | 55.29M |
| June 30, 2022 | 63.51M |
| December 31, 2021 | -11.64M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-11.64M
Minimum
Dec 2021
542.55M
Maximum
Mar 2024
267.17M
Average
244.22M
Median
Shareholders Equity (Quarterly) Benchmarks
| Novartis AG | 43.32B |
| AC Immune SA | 137.30M |
| CRISPR Therapeutics AG | 1.981B |
| Addex Therapeutics Ltd | 14.07M |
| NLS Pharmaceutics Ltd | -9.268M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 544.88M |
| Total Liabilities (Quarterly) | 14.85M |